Common Stock, par value $0.0001 per share
- Symbol
- CDXS
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 8.01 · 8-K
Codexis, Inc.
CDXSNASDAQEQUITYCurrent
Results of Operations and Financial Condition · Other Events
Item 2.02. Results of Operations and Financial Condition. On July 23, 2026, Codexis, Inc. (the “Company”) disclosed that it expects to report total revenue for the three months ended June 30, 2026 to be at least $14.8 million, and cash, cash equivalents and short-term investments as of June 30, 2026 of approximately $54.9 million.…
Company context
Codexis® is a leading provider of high-performance enzymatic solutions for efficient and scalable therapeutics manufacturing. The company is currently developing its proprietary ECO Synthesis® Manufacturing Platform, an aqueous enzymatic process that may offer a scalable alternative to traditional solid phase organic synthesis of oligonucleotide manufacturing. Initially, Codexis is applying its technology to address the rapidly growing demand for RNAi therapeutics. Codexis’ unique enzymes can drive improvements such as higher yields, increased purity, reduced energy usage and waste generation, stereoisomer control of siRNA, and improved overall capacity in manufacturing at substantially lower capital requirements, all of which may lead to greater efficiency and reduced costs. In addition, the company supplies high-performance enzymes through its BioCatalysis business that are used in the manufacture of multiple commercially available small molecule therapeutics. For additional information, please visit https://www.codexis.com.
Current securities
Recent company filings
- 10-Q filingNov 12, 2026
- Results of Operations and Financial ConditionNov 12, 2026
- Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity SecuritiesNov 10, 2026
- 10-Q filingAug 11, 2026
- Results of Operations and Financial ConditionAug 11, 2026
Registered securities in this filing
Codexis, Inc. · 8-K · Filed 2026-07-23
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02. Results of Operations and Financial Condition.
On July 23, 2026, Codexis, Inc. (the “Company”) disclosed that it expects to report total revenue for the three months ended June 30, 2026 to be at least $14.8 million, and cash, cash equivalents and short-term investments as of June 30, 2026 of approximately $54.9 million. These amounts are preliminary and subject to completion of the Company’s financial closing procedures, including the completion of management’s reviews. Accordingly, the amounts set forth above reflect the Company’s preliminary estimates with respect to such information, based on information currently available to management as of the date of this report, and may vary from the Company’s actual financial position and results as of and for the quarter ended June 30, 2026. In addition, the Company’s independent registered public accounting firm has not audited, reviewed, compiled or performed any procedures with respect to this unaudited preliminary financial information and does not express an opinion or any other form of assurance with respect thereto. Additional information and disclosures would be required for a more complete understanding of the Company’s financial condition, liquidity and results of operations as of and for the quarter ended June 30, 2026.
Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events.
The information contained in Item 2.02 above is incorporated herein by reference.